BeiGene Secures Worldwide Licensing Deal with CSPC Zhongqi Pharma for MAT2A Inhibitor in Solid Tumor Treatment
BeiGene, Ltd., soon to be rebranded as BeOne Medicines Ltd., has disclosed a global licensing deal with CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. (CSPC) for SYH2039. This innovative methionine adenosyltransferase 2A (MAT2A) inhibitor is in exploration for potential uses […]